Bod to supply medicinal cannabis for a PTSD trial
Written on the 4 June 2019 by Business News Australia
Listed medicinal cannabis healthcare company Bod Australia (ASX: BDA) will supply its cannabis extract, MediCabilis, to sufferers of Post Traumatic Stress Disorder (PTSD) in a landmark trial.
Research partner Cannabis Access Clinics is facilitating the trial looking into how medicinal cannabis can treat symptoms of the psychological disorder.
PTSD is estimated to affect around 12 per cent of Australians and is a particular set of reactions that can develop in people who have experienced a traumatic event. As a result, sufferers can develop feelings of intense fear, helplessness and horror.
The trial will see MediCabilis prescribed to patients through approved prescribers in the Cannabis Access Clinics network.
The drug doesn't come cheap though - patients can expect to pay $491 for the product.
Cannabis Access Clinics medical director Dr Nijhawan says the trial has the potential to be transformative for those who suffer from PTSD.
"We have first-hand experience treating symptoms of PTSD and seeing the positive effects that medicinal cannabis can have on patient outcomes," says Dr Nijhawan.
"This study will provide valuable insight into how medicinal cannabis is being used and its effect on patient outcomes. It will help build on existing evidence and support further research and clinical applications. CBD has fewer side effects than the pharmacological therapy currently used, even at higher doses."
Bod Australia CEO Jo Patterson welcomes the trial from both a treatment and revenue perspective.
"PTSD is widespread and debilitating on a global scale," says Patterson.
"The Australian Defence Force has reported that an estimated 90 per cent of members have experienced at least one potentially traumatic event at some time of their life, which may result in symptoms of PTSD."
"We look forward to progressing this trial as it has the potential to significantly strengthen our revenue stream, as well as further validate our product suite."
Business News Australia
Author: Business News Australia